- Home
- ATNF vs SNGX Comparison
ATNF vs SNGX Comparison
Compare ATNF & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- SNGX
- Stock Information
- Founded
- ATNF 2016
- SNGX 1987
- Country
- ATNF United States
- SNGX United States
- Employees
- ATNF N/A
- SNGX N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- SNGX Health Care
- Exchange
- ATNF Nasdaq
- SNGX Nasdaq
- Market Cap
- ATNF 5.0M
- SNGX 4.3M
- IPO Year
- ATNF N/A
- SNGX 1987
- Fundamental
- Price
- ATNF $3.52
- SNGX $1.25
- Analyst Decision
- ATNF
- SNGX Strong Buy
- Analyst Count
- ATNF 0
- SNGX 1
- Target Price
- ATNF N/A
- SNGX $6.00
- AVG Volume (30 Days)
- ATNF 6.6M
- SNGX 255.8K
- Earning Date
- ATNF 07-23-2025
- SNGX 08-12-2025
- Dividend Yield
- ATNF N/A
- SNGX N/A
- EPS Growth
- ATNF N/A
- SNGX N/A
- EPS
- ATNF N/A
- SNGX N/A
- Revenue
- ATNF N/A
- SNGX $2,342.00
- Revenue This Year
- ATNF N/A
- SNGX N/A
- Revenue Next Year
- ATNF N/A
- SNGX N/A
- P/E Ratio
- ATNF N/A
- SNGX N/A
- Revenue Growth
- ATNF N/A
- SNGX N/A
- 52 Week Low
- ATNF $0.66
- SNGX $1.09
- 52 Week High
- ATNF $17.75
- SNGX $5.40
- Technical
- Relative Strength Index (RSI)
- ATNF 78.48
- SNGX 37.45
- Support Level
- ATNF $2.55
- SNGX $1.18
- Resistance Level
- ATNF $4.75
- SNGX $1.46
- Average True Range (ATR)
- ATNF 0.81
- SNGX 0.09
- MACD
- ATNF 0.21
- SNGX 0.01
- Stochastic Oscillator
- ATNF 68.24
- SNGX 25.00
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).